- Home
- BXP vs ARWR Comparison
BXP vs ARWR Comparison
Compare BXP & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BXP | ARWR |
|---|---|---|
| Founded | 1970 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 9.6B |
| IPO Year | 1997 | 1993 |
Fundamental Metrics
Financial Performance| Metric | BXP | ARWR |
|---|---|---|
| Price | $71.45 | $69.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 10 |
| Target Price | ★ $77.61 | $60.70 |
| AVG Volume (30 Days) | 1.2M | ★ 3.3M |
| Earning Date | 01-27-2026 | 11-25-2025 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,425,025,000.00 | $829,448,000.00 |
| Revenue This Year | $3.60 | N/A |
| Revenue Next Year | $1.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.42 | ★ 23258.15 |
| 52 Week Low | $54.22 | $9.57 |
| 52 Week High | $81.59 | $72.36 |
Technical Indicators
Market Signals| Indicator | BXP | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 73.86 |
| Support Level | $68.04 | $68.01 |
| Resistance Level | $72.50 | $72.36 |
| Average True Range (ATR) | 1.44 | 4.99 |
| MACD | 0.13 | 1.06 |
| Stochastic Oscillator | 67.84 | 88.20 |
Price Performance
Historical ComparisonAbout BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.